Us Bancorp \De\ Wave Life Sciences Ltd. Transaction History

Us Bancorp \De\

$77.3 Billion
Q3 2024

A detailed history of Us Bancorp \De\ transactions in Wave Life Sciences Ltd. stock. As of the latest transaction made, Us Bancorp \De\ holds 18,043 shares of WVE stock, worth $241,956. This represents 0.0% of its overall portfolio holdings.

Number of Shares

18,043

Previous 11,727 53.86%

Holding current value

$241,956

Previous $58,000 153.45%

% of portfolio

0.0%

Previous 0.0%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 28, 2024	BUY	$5.12 - $9.01 $32,337 - $56,907	6,316 Added 53.86%	18,043 $147,000
Q2 2024 Aug 06, 2024	BUY	$4.38 - $6.48 $48,158 - $71,247	10,995 Added 1502.05%	11,727 $58,000
Q4 2023 Feb 09, 2024	BUY	$4.16 - $6.87 $3,045 - $5,028	732 New	732 $3,000
Q2 2022 Aug 01, 2022	SELL	$1.23 - $3.25 $5,574 - $14,729	-4,532 Closed	0 $0
Q1 2022 May 11, 2022	BUY	$2.0 - $3.28 $3,676 - $6,028	1,838 Added 68.23%	4,532 $9,000
Q4 2021 Feb 11, 2022	BUY	$3.14 - $5.15 $5,400 - $8,858	1,720 Added 176.59%	2,694 $8,000
Q3 2021 Nov 10, 2021	BUY	$4.89 - $7.12 $821 - $1,196	168 Added 20.84%	974 $5,000
Q2 2021 Aug 05, 2021	BUY	$5.65 - $7.47 $4,553 - $6,020	806 New	806 $5,000
Q4 2020 Feb 04, 2021	SELL	$6.99 - $9.26 $1,516 - $2,009	-217 Closed	0 $0
Q3 2020 Nov 10, 2020	BUY	$8.49 - $19.54 $1,842 - $4,240	217 New	217 $2,000
Q2 2020 Aug 07, 2020	SELL	$7.44 - $11.29 $424 - $643	-57 Closed	0 $0
Q1 2020 May 13, 2020	BUY	$6.94 - $14.22 $395 - $810	57 New	57 $1,000
Q2 2019 Aug 13, 2019	SELL	$22.93 - $42.84 $1,811 - $3,384	-79 Closed	0 $0
Q1 2019 May 08, 2019	BUY	$32.69 - $47.91 $2,582 - $3,784	79 New	79 $3,000

Others Institutions Holding WVE

# of Institutions

164

Shares Held

117M

Call Options Held

148K

Put Options Held

109K

View Full List

About Wave Life Sciences Ltd.

Ticker WVE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 86,820,096
Market Cap $1.16B
Description
Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. It is developing oligonucleotides target ribonucleic acid to reduce the expression of disease-promoting proteins or restore the production of functional pr...

More about WVE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Us Bancorp \De\, based on Form 13F filings with the SEC.

News

Stay updated on Us Bancorp \De\ with notifications on news.

Account